The government is raising its hopes for a mass supply at the Serum Institute, which filed its first formal plea for emergency-use approval for Monday’s AstraZeneca shot.
Chief Executive Officer Adar Poonawalla said the vaccine was priced at Rs 1,000 ($ 13.55) per dose in the Indian private market, but that it would be cheaper for governments to sign larger supply contracts, Business Standard reported.
Poonawalla said the focus would be on first delivering the vaccine to Indians before delivering the vaccine to other countries.
With 9.70 million cases of Covid-19 so far, India is second only to the United States and is stepping up vaccines developed by Pfizer Inc. and AstraZeneca to authorize emergency use, a senior official said on Monday.
The Government-run Indian Medical Research Council, the Serum Institute and the Indian Ministry of Health did not immediately respond to Reuters’ request. ($ 1 = 73.8060 Indian rupees)